Tibet Cheezheng Tibetan Medicine Co., Ltd.
Symbol: 002287.SZ
SHZ
22.21
CNYDzisiejsza cena rynkowa
20.1008
Wskaźnik P/E
0.0000
Wskaźnik PEG
11.78B
Kapitalizacja MRK
- 0.02%
Rentowność DIV
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287-SZ) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10005.55 | 2366.5 | 1976.9 | 1850.6 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 8430.88 | 1963 | 1539.3 | 1184 | ||||||||||||||||||
balance-sheet.row.net-receivables | 3258.11 | 663.5 | 841.2 | 629.6 | ||||||||||||||||||
balance-sheet.row.inventory | 642.83 | 156.3 | 127.8 | 118.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 87.71 | 8 | 246.6 | 337.7 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 14048.36 | 3194.4 | 3192.4 | 2936.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5861.27 | 1651.6 | 1144.4 | 821.4 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -561.9 | 1056.5 | -423.1 | -42.4 | ||||||||||||||||||
balance-sheet.row.tax-assets | 139.57 | 39.4 | 29.1 | 26.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 5055.39 | 4.9 | 1568.9 | 1426.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11907.61 | 3104.1 | 2694.2 | 2631.4 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.account-payables | 744.05 | 255.6 | 93.5 | 184 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 3466.68 | 478 | 762.3 | 610.8 | ||||||||||||||||||
balance-sheet.row.tax-payables | 237.12 | 55.6 | 61.9 | 37.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 4253.1 | 1061.3 | 934.4 | 841.4 | ||||||||||||||||||
Deferred Revenue Non Current | 754.86 | 191.3 | 167 | 154.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 127.94 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 460.38 | 437.7 | 402.2 | 4.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 4959.4 | 1089.2 | 1138.9 | 1039.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 21.98 | 7 | 4.9 | 4.9 | ||||||||||||||||||
balance-sheet.row.total-liab | 11067.61 | 2334.4 | 2499 | 2347.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 471.98 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 2120.75 | 530.2 | 530.2 | 530.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 8154.57 | 2104.1 | 1784.8 | 1667 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2375.97 | 631.3 | 566.4 | 507.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1369.17 | 454.7 | 454.6 | 464.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 14492.44 | 3720.3 | 3336 | 3169 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.minority-interest | 202.02 | 49.8 | 51.6 | 51.4 | ||||||||||||||||||
balance-sheet.row.total-equity | 14694.46 | 3770.1 | 3387.7 | 3220.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 25955.97 | - | - | - | ||||||||||||||||||
Total Investments | 5660.63 | 3019.6 | 1116.2 | 1141.6 | ||||||||||||||||||
balance-sheet.row.total-debt | 7726.78 | 1546.3 | 1696.7 | 1452.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 6152.1 | 1142.9 | 1259.1 | 785.6 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 585.9 | 581.2 | 469.5 | 710.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 7.51 | 95.8 | 83.2 | 65.8 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -17.2 | -24.3 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0.87 | -168.3 | 3.6 | 4.9 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 38 | 47.8 | -374.7 | 521.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 41.95 | 42 | -209.3 | 369.7 | ||||||||||||||||||
cash-flows.row.inventory | -28.46 | -28.5 | -10.6 | -24 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 9.8 | -146.4 | 136.6 | ||||||||||||||||||
cash-flows.row.other-working-capital | 24.51 | 24.5 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 320.18 | 439.6 | 112.5 | -306.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 934.39 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.acquisitions-net | -0.56 | -0.6 | -3.8 | -61.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1450 | -1492.4 | -1418 | -3494.7 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1063.16 | 1138.1 | 1355.9 | 1526 | ||||||||||||||||||
cash-flows.row.other-investing-activites | -229.98 | 0 | 3.8 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -642.34 | -589.7 | -334.5 | -2155.4 | ||||||||||||||||||
cash-flows.row.debt-repayment | -1492.91 | -201.8 | -637.8 | -341.8 | ||||||||||||||||||
cash-flows.row.common-stock-issued | -250.46 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -219.61 | -206.7 | -340.5 | -195.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 1205.14 | -13.3 | 795.1 | 494.6 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -92.13 | -431.9 | -183.2 | -42.8 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.14 | 0.6 | 3 | -0.7 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 215.99 | -34.1 | -229.1 | -1164 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1573.63 | 403.4 | 437.6 | 666.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1357.64 | 437.6 | 666.6 | 1830.6 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 934.39 | 971.9 | 285.7 | 1034.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 679.46 | 737.1 | 13.3 | 909.3 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 2101.04 | 2010.3 | 2044.8 | 1770.5 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 349.53 | 382.4 | 324.1 | 265.3 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1751.51 | 1627.9 | 1720.6 | 1505.1 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 58 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 52.87 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 1191.78 | 1161.6 | 1118.9 | 1007.3 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1541.31 | 1544 | 1443.1 | 1272.6 | ||||||||||||||||||
income-statement-row.row.interest-income | 10.54 | 13.1 | 17 | 34.4 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 61.27 | 95.8 | 143.9 | 111 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 598.17 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 569.73 | 466.3 | 521.5 | 790.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 672.15 | 642.5 | 519.2 | 787.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 73.04 | 65.2 | 49.7 | 77.1 | ||||||||||||||||||
income-statement-row.row.net-income | 585.9 | 581.2 | 472.5 | 715.9 |
Często zadawane pytania
Ile wynosi Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) aktywów ogółem?
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) całkowite aktywa to 6298478593.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 1150739074.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.834.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 1.281.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.279.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.271.
Co to jest Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 581198850.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 1546314759.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 1161615874.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 357241866.000.